Bausch Health and its gastroenterology business, Salix Pharmaceuticals announced the U.S. Patent and Trademark Office has issued an additional patent covering the use of XIFAXAN® (rifaximin) 550 mg tablets to treat symptoms of Irritable Bowel Syndrome (IBS). The patent issued is United States Patent No. 10,456,384, entitled "Methods for Treating Irritable Bowel Syndrome (IBS)." Final expiry of the new patent covering IBS is in February 2029.
"We have always been confident in the strength of the XIFAXAN patents, and the addition of this new patent specific to the treatment of IBS further strengthens our XIFAXAN intellectual property," said Joseph C. Papa, chairman and CEO, Bausch Health. "We will continue to vigorously defend our intellectual property."
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
XIFAXAN is now protected by 23 patents covering the composition of matter and the use of XIFAXAN listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book.
XIFAXAN (rifaximin) 550 mg tablets are indicated for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults and for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults.